Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Children's Hospital/USC School of Medicine
mi
from
Los Angeles, CA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Children's Hospital/USC School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Children's Hospital and Research Center
mi
from
Oakland, CA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Children's Hospital and Research Center
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
UCSD/San Diego Children's Hospital
mi
from
San Diego, CA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
UCSD/San Diego Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Diabetes Center at UCSF
mi
from
San Francisco, CA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Diabetes Center at UCSF
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Barbara Davis Center for Childhood Diabetes, University of Colorado
mi
from
Aurora, CO
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Barbara Davis Center for Childhood Diabetes, University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Emory Children's Center
mi
from
Atlanta, GA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Emory Children's Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
University of Pennsylvania/Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
University of Pennsylvania/Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated:  1/15/2016
Anthony Jordan Health Center
mi
from
Rochester, NY
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated: 1/15/2016
Anthony Jordan Health Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated:  1/15/2016
Rochester General Medical Associates
mi
from
Rochester, NY
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated: 1/15/2016
Rochester General Medical Associates
mi
from
Rochester, NY
Click here to add this to my saved trials
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated:  1/15/2016
Unity Health System
mi
from
Rochester, NY
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated: 1/15/2016
Unity Health System
mi
from
Rochester, NY
Click here to add this to my saved trials
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated:  1/15/2016
Westside Health Services
mi
from
Rochester, NY
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated: 1/15/2016
Westside Health Services
mi
from
Rochester, NY
Click here to add this to my saved trials
Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500
A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix 75/25 in Subjects With Type 2 Diabetes Mellitus Who Are Treated With 50-200 Units of Insulin Per Day
Status: Enrolling
Updated:  1/15/2016
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500
A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix 75/25 in Subjects With Type 2 Diabetes Mellitus Who Are Treated With 50-200 Units of Insulin Per Day
Status: Enrolling
Updated: 1/15/2016
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Status: Enrolling
Updated:  1/19/2016
Indiana Clinical Research Center
mi
from
Indianapolis, IN
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Status: Enrolling
Updated: 1/19/2016
Indiana Clinical Research Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated:  1/19/2016
Novartis Investigative Site
mi
from
New York City, NY
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated: 1/19/2016
Novartis Investigative Site
mi
from
New York City, NY
Click here to add this to my saved trials
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated:  1/19/2016
Novartis Investigative Site
mi
from
Seattle, WA
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated: 1/19/2016
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated:  1/19/2016
Novartis Investigative Site
mi
from
Seattle, WA
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated: 1/19/2016
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Endocrinology Associates
mi
from
Montgomery, AL
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Endocrinology Associates
mi
from
Montgomery, AL
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Diabetes and Endocrine Consultants P.C.
mi
from
Montgomery, AL
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Diabetes and Endocrine Consultants P.C.
mi
from
Montgomery, AL
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
University of Miami, Diabetes Research Institute
mi
from
Miami, FL
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
University of Miami, Diabetes Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Dr. Rife and Associates Family Medicine
mi
from
Orland Park, IL
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Dr. Rife and Associates Family Medicine
mi
from
Orland Park, IL
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Highland Clini-Endocrinology
mi
from
Shreveport, LA
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Highland Clini-Endocrinology
mi
from
Shreveport, LA
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Annapolis Internal Medicine LLC
mi
from
Annapolis, MD
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Annapolis Internal Medicine LLC
mi
from
Annapolis, MD
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Nallin Family Healthcare
mi
from
Cumberland, MD
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Nallin Family Healthcare
mi
from
Cumberland, MD
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Center for Diabetes and Endocrinology
mi
from
Portsmouth, NH
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Center for Diabetes and Endocrinology
mi
from
Portsmouth, NH
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
North Country Community Physicians
mi
from
Glen Cove, NY
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
North Country Community Physicians
mi
from
Glen Cove, NY
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Great Neck Medical Group
mi
from
Great Neck, NY
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Great Neck Medical Group
mi
from
Great Neck, NY
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
North Shore Diabetes and Endocrine Associates
mi
from
New Hyde Park, NY
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
North Shore Diabetes and Endocrine Associates
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Mountain Diabetes & Endocrine Center
mi
from
Asheville, NC
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Mountain Diabetes & Endocrine Center
mi
from
Asheville, NC
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Primary Care Wakefield
mi
from
Wakefield, RI
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Primary Care Wakefield
mi
from
Wakefield, RI
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Endocrinology Associates Inc.
mi
from
Roanoke, VA
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Endocrinology Associates Inc.
mi
from
Roanoke, VA
Click here to add this to my saved trials
Empowering Rural African American Women and Communities to Improve Diabetes Outcomes
Empowering Rural African American Women and Communities to Improve Diabetes Outcomes
Status: Enrolling
Updated:  1/19/2016
East Carolina University
mi
from
Greenville, NC
Empowering Rural African American Women and Communities to Improve Diabetes Outcomes
Empowering Rural African American Women and Communities to Improve Diabetes Outcomes
Status: Enrolling
Updated: 1/19/2016
East Carolina University
mi
from
Greenville, NC
Click here to add this to my saved trials
Text Messaging for Weight Loss
The Comparative Effectiveness of Clinic-Based Weight Loss Strategies
Status: Enrolling
Updated:  1/19/2016
Denver Health
mi
from
Denver, CO
Text Messaging for Weight Loss
The Comparative Effectiveness of Clinic-Based Weight Loss Strategies
Status: Enrolling
Updated: 1/19/2016
Denver Health
mi
from
Denver, CO
Click here to add this to my saved trials
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  1/21/2016
Novo Nordisk Clinical Trial Call Center
mi
from
Minneapolis, MN
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 1/21/2016
Novo Nordisk Clinical Trial Call Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1276.1.10044 Boehringer Ingelheim Investigational Site
mi
from
Hot Springs, AK
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1276.1.10044 Boehringer Ingelheim Investigational Site
mi
from
Hot Springs, AK
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1301.1.5727 Boehringer Ingelheim Investigational Site
mi
from
Glendale, AZ
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1301.1.5727 Boehringer Ingelheim Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1276.1.10035 Boehringer Ingelheim Investigational Site
mi
from
Searcy, AR
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1276.1.10035 Boehringer Ingelheim Investigational Site
mi
from
Searcy, AR
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1218.64.10007 Boehringer Ingelheim Investigational Site
mi
from
Chula Vista, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1218.64.10007 Boehringer Ingelheim Investigational Site
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1222.29.11006 Boehringer Ingelheim Investigational Site
mi
from
Huntington Beach, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1222.29.11006 Boehringer Ingelheim Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1245.19.10047 Boehringer Ingelheim Investigational Site
mi
from
La Mesa, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1245.19.10047 Boehringer Ingelheim Investigational Site
mi
from
La Mesa, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1220.48.0018 Boehringer Ingelheim Investigational Site
mi
from
Oceanside, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1220.48.0018 Boehringer Ingelheim Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1268.17.01015 Boehringer Ingelheim Investigational Site
mi
from
Colorado Springs, CO
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1268.17.01015 Boehringer Ingelheim Investigational Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1245.20.10038 Boehringer Ingelheim Investigational Site
mi
from
Northglenn, CO
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1245.20.10038 Boehringer Ingelheim Investigational Site
mi
from
Northglenn, CO
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials